Gentian Diagnostics AS (GENT) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Gentian Diagnostics AS NOK 40.92, price NOK 37.90, upside +8.0%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Gentian Diagnostics AS for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 34.60 – kr 84.16 · fair‑value band kr 28.65 – kr 53.21 · the kr 37.90 price screens below the kr 40.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Gentian Diagnostics AS in your weekly email
Every Wednesday you see whether Gentian Diagnostics AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe.
Show more
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
Stock analysis
Gentian Diagnostics AS (GENT) currently trades at kr 37.90, while our model-based Fair Value estimate is kr 40.92, implying the stock looks roughly 7.4% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 42.81 per share, and 11 of the 26 models we run sit above the kr 37.90 price.
Bear case: the Dividend Discount group reads lowest at kr 4.42, and 15 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: kr 28.65 (bear) to kr 53.21 (bull), the price of kr 37.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Gentian Diagnostics AS reported revenue of 176M NOK in FY2025 versus 83.1M NOK in FY2021, a compound +20.7%/yr. Reported net income was 13.3M NOK in FY2025.
Key figures
Market cap 585M NOK (≈ $61.4M) · P/S ratio 3.23 · EPS (TTM) kr −0.5500 · Dividend yield 1.6% · Net margin 7.5% · Return on equity −4.4% · Return on assets (EBIT) −2.7% · Operating margin 11.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 8%, GENT screens cheaper than that median.
Fair Value models
Bear kr 28.65Fair Value kr 40.92Bull kr 53.21
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+16.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.9%
Start year 2020 (pandemic). Over 10 years: +21.3% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.1% (2020) → 14.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Norway: IMF forecast 2.4% a year to 2030, 3.3% from 2016 to 2025) that is about +5.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+10% · Above median
Profitability
Return on assets6% · Top 25%
Net margin (TTM)−5% · Below median
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth14% · Above median
Dividend yield (TTM)1.6% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Gentian Diagnostics AS Fair Value". https://www.fairvalue-calculator.com/stock/GENT
Frequently asked questions
Is Gentian Diagnostics AS (GENT) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 40.92 versus a price of kr 37.90, about +8% upside (fairly valued).
What is the fair value of GENT?
Our model-based fair value for Gentian Diagnostics AS is kr 40.92 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 37.90.
What is the quality score of GENT?
Gentian Diagnostics AS has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gentian Diagnostics AS (GENT)?
Our model-based price target is the fair value of kr 40.92 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario kr 28.65, optimistic scenario kr 53.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Gentian Diagnostics AS stock forecast for 2026?
Our models put fair value at kr 40.92, about +8% upside versus a price of kr 37.90 (fairly valued). Cautious scenario kr 28.65, optimistic scenario kr 53.21. The calculation is refreshed regularly with new filings.
What is the revenue of Gentian Diagnostics AS (GENT)?
Gentian Diagnostics AS reported trailing-twelve-month revenue of about 182M NOK (latest available figure, as of Sep 24, 2026).
Does Gentian Diagnostics AS pay a dividend?
Gentian Diagnostics AS currently shows a dividend yield of about 1.58% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Gentian Diagnostics AS (GENT)?
For today's price to be fair in a discounted-cash-flow model, Gentian Diagnostics AS would have to grow free cash flow by +8.1 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +20.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of GENT use?
Our models discount Gentian Diagnostics AS at 11.0 %: a base by market capitalisation (micro), damped by beta 0.45, country premium for Norway. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Gentian Diagnostics AS that is +8.1 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Gentian Diagnostics AS (GENT) delivered so far?
Over the past 5 years revenue at Gentian Diagnostics AS grew +20.9 % a year. The price currently implies +8.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Gentian Diagnostics AS (GENT) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Gentian Diagnostics AS (+8.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Gentian Diagnostics AS (GENT)?
The free-cash-flow yield on the price is 5.45 %: that much free cash flow Gentian Diagnostics AS produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Gentian Diagnostics AS (GENT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gentian Diagnostics AS it is kr 40.92 per share (as of Sep 24, 2026), against a price of kr 37.90. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Gentian Diagnostics AS stock overvalued or undervalued in 2026?
As of Sep 24, 2026, GENT trades below its calculated fair value: price kr 37.90, fair value kr 40.92, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GENT?
No. The price is what the market pays today (kr 37.90); the fair value is what the company's own numbers justify (kr 40.92). For Gentian Diagnostics AS the two are kr 3.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gentian Diagnostics AS worth?
The market values Gentian Diagnostics AS at about 585M NOK (market capitalisation, as of Sep 24, 2026). Per share that is kr 37.90; our models calculate a fair value of kr 40.92 per share.
What do the bullish and bearish scenarios say about GENT?
Our models span a range for Gentian Diagnostics AS: cautious scenario kr 28.65, base kr 40.92, optimistic kr 53.21 per share (as of Sep 24, 2026, price kr 37.90). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Gentian Diagnostics AS (GENT)?
Balance-sheet figures for Gentian Diagnostics AS (as of Sep 24, 2026): return on equity −4.4%. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is GENT from its 52-week high?
Gentian Diagnostics AS trades at kr 37.90, about 35% below its 52-week high of kr 58.21 and 10% above the low of kr 34.60 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 40.92 is for.
Which stocks are comparable to Gentian Diagnostics AS?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gentian Diagnostics AS stock attractive at the current price?
The data as of Sep 24, 2026: price kr 37.90, calculated fair value kr 40.92 (+8%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GENT calculated?
We run Gentian Diagnostics AS through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 40.92, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Gentian Diagnostics AS currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gentian Diagnostics AS (GENT)?
The closing price on Sep 24, 2026 was kr 37.90. Our model-based fair value is kr 40.92, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gentian Diagnostics AS right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (kr 28.65 to kr 53.21) leaves room in how you read the outcome.
Key figures of Gentian Diagnostics AS
How large is the market capitalisation of Gentian Diagnostics AS (GENT)?
The market capitalisation of Gentian Diagnostics AS is 585M NOK (≈ $61.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gentian Diagnostics AS (GENT)?
The price-to-sales ratio of Gentian Diagnostics AS is 3.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gentian Diagnostics AS (GENT)?
Earnings per share at Gentian Diagnostics AS are kr −0.5500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Gentian Diagnostics AS (GENT)?
The dividend yield of Gentian Diagnostics AS is 1.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Gentian Diagnostics AS (GENT)?
The net margin of Gentian Diagnostics AS is 7.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gentian Diagnostics AS (GENT)?
The return on equity (ROE) of Gentian Diagnostics AS is −4.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gentian Diagnostics AS (GENT)?
On an EBIT basis the return on assets of Gentian Diagnostics AS is −2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gentian Diagnostics AS (GENT)?
The operating margin of Gentian Diagnostics AS is 11.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gentian Diagnostics AS (GENT)?
Revenue at Gentian Diagnostics AS is growing +14.2% versus a year earlier (3y avg +20.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gentian Diagnostics AS (GENT)?
Earnings per share at Gentian Diagnostics AS are growing −89.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Gentian Diagnostics AS (GENT) hold?
Gentian Diagnostics AS holds more cash than debt, 74.7M NOK net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Gentian Diagnostics AS in the live analysis
One click puts Gentian Diagnostics AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
